Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "Momentum"

313 News Found

BioNTech maps pivotal oncology milestones for 2026
News | January 15, 2026

BioNTech maps pivotal oncology milestones for 2026

BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company


PHARMEXCIL holds high-level talks with government to boost India’s pharma exports
News | January 06, 2026

PHARMEXCIL holds high-level talks with government to boost India’s pharma exports

India’s pharmaceutical sector stands at a pivotal inflection point


Dabur sees early demand recovery, rural sales lead growth in Q3 FY26
News | January 06, 2026

Dabur sees early demand recovery, rural sales lead growth in Q3 FY26

Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,


CORONA Remedies posts double-digit growth in Q2, H1 FY26; PAT surges up to 35%
News | January 03, 2026

CORONA Remedies posts double-digit growth in Q2, H1 FY26; PAT surges up to 35%

The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half


Cupid reports record Q3, eyes GCC expansion with Saudi FMCG facility
News | January 03, 2026

Cupid reports record Q3, eyes GCC expansion with Saudi FMCG facility

Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity


SN Bioscience’s SNB-101 wins FDA orphan drug designation for gastric cancer
Clinical Trials | December 29, 2025

SN Bioscience’s SNB-101 wins FDA orphan drug designation for gastric cancer

The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38


Cupid reduces promoter pledged stake to 20%
News | December 23, 2025

Cupid reduces promoter pledged stake to 20%

This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence


Soligenix publishes promising Phase 2a data for SGX945 in Behcet's Disease
Clinical Trials | December 21, 2025

Soligenix publishes promising Phase 2a data for SGX945 in Behcet's Disease

SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers